Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 2:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,178 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo Tablet: BID Clear all
Completed Phase 3 Interventional Results available

A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

NCT00105443
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Sorafenib (Nexavar, BAY43-9006), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
35
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Sep 15, 2026, 2:08 AM EDT
Completed Phase 2 Interventional Results available

Exploratory Study to Access the Metabolic Effects of Ranolazine in Subjects With Type 2 Diabetes Mellitus When Added to Ongoing Non-insulin Antidiabetic Therapy

NCT01163721
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
9
States / cities
Escondido, California • Los Angeles, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2013 · Synced Sep 15, 2026, 2:08 AM EDT
Completed Phase 3 Interventional Results available

A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)

NCT03449147
View directory record Official record
Conditions
Chronic Cough
Interventions
Placebo, Gefapixant 15 mg BID, Gefapixant 45 mg BID
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
34
States / cities
Peoria, Arizona • Phoenix, Arizona • Tempe, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Sep 15, 2026, 2:08 AM EDT
Completed Phase 4 Interventional Results available

A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis

NCT01356940
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
dalfampridine ER, placebo
Drug
Lead sponsor
Brown, Theodore R., M.D., MPH
Individual
Eligibility
18 Years to 75 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Sep 15, 2026, 2:08 AM EDT
Completed Phase 2 Interventional Results available

The Effects of Potassium on Glucose Metabolism in African Americans

NCT02236598
View directory record Official record
Conditions
Borderline Hypokalemia
Interventions
K+ supplement, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
30 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Sep 15, 2026, 2:08 AM EDT
Completed Phase 3 Interventional Results available

The Mycotic Ulcer Treatment Trial II: A Randomized Trial Comparing Oral Voriconazole vs Placebo

NCT00997035
View directory record Official record
Conditions
Corneal Ulcer, Eye Infections, Fungal
Interventions
Voriconazole, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
16 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Sep 15, 2026, 2:08 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Comparison of Bupropion SR and Placebo for Smoking Cessation

NCT00176449
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Bupropion SR, Placebo Oral Tablet
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2005
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 15, 2019 · Synced Sep 15, 2026, 2:08 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata

NCT03941548
View directory record Official record
Conditions
Alopecia Areata
Interventions
CTP-543, CTP-543 Matching Placebo
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
Centennial, Colorado • Tampa, Florida • Plainfield, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Sep 15, 2026, 2:08 AM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

NCT01539512
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Idelalisib, Rituximab, Placebo to match idelalisib
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
34
States / cities
Huntsville, Alabama • Tucson, Arizona • La Jolla, California + 27 more
Source: ClinicalTrials.gov public record
Updated May 13, 2019 · Synced Sep 15, 2026, 2:08 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis

NCT06887192
View directory record Official record
Conditions
Psychosis Associated With Alzheimer's Disease
Interventions
ML-007C-MA, Placebo
Drug
Lead sponsor
MapLight Therapeutics
Industry
Eligibility
55 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
34
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 15, 2026, 2:08 AM EDT
Completed Phase 2 Interventional Results available

A Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at Three Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium

NCT00949975
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
AZD9668, AZD9668 Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 80 Years
Enrollment
838 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
9
States / cities
Fullerton, California • Valparaiso, Indiana • Council Bluffs, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2012 · Synced Sep 15, 2026, 2:08 AM EDT
Completed Phase 3 Interventional Results available

Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma

NCT00901901
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Sorafenib (Nexavar, BAY43-9006), Erlotinib (Tarceva), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
23
States / cities
San Francisco, California • Washington D.C., District of Columbia • Gainesville, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Sep 15, 2026, 2:08 AM EDT
Terminated Phase 2 Interventional Results available

PBI-0451 (Pomotrelvir) Phase 2 Study in Nonhospitalized Symptomatic Adults With COVID-19

NCT05543707
View directory record Official record
Conditions
COVID-19
Interventions
PBI-0451 (Pomotrelvir), Placebo
Drug
Lead sponsor
Pardes Biosciences, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
54
States / cities
Mesa, Arizona • Bakersfield, California • Canoga Park, California + 41 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Sep 15, 2026, 2:08 AM EDT
Completed Phase 2 Interventional

A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients

NCT01487109
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Disease
Interventions
CTP-499, Placebo
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
49
States / cities
Tempe, Arizona • Harrisburg, Arkansas • Little Rock, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2021 · Synced Sep 15, 2026, 2:08 AM EDT
Suspended Phase 3 Interventional Results available

A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR)

NCT04104321
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
Aramchol free acid, Placebo
Drug
Lead sponsor
Galmed Research and Development, Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Miami, Florida • Arlington, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Sep 15, 2026, 2:08 AM EDT
Withdrawn Phase 3 Interventional

To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MS

NCT02869425
View directory record Official record
Conditions
Multiple Sclerosis, Sperm
Interventions
arbaclofen ER Tablets, Placebo for arbaclofen ER tablets
Drug
Lead sponsor
RVL Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Miami, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced Sep 15, 2026, 2:08 AM EDT
Completed Phase 3 Interventional

PrEvention of Posttraumatic Joint contractuRes With Ketotifen 2

NCT03582176
View directory record Official record
Conditions
Elbow Fracture, Elbow Injury, Elbow Dislocation
Interventions
Lactose Placebo, Ketotifen Fumarate 2mg, Ketotifen Fumarate 5mg
Drug
Lead sponsor
University of Calgary
Other
Eligibility
18 Years to 95 Years
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
Baltimore, Maryland • Charlotte, North Carolina • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 15, 2026, 2:08 AM EDT
Recruiting Phase 4 Interventional

Hydroxycitrate: A Novel Therapy for Calcium Phosphate Urinary Stones

NCT06003348
View directory record Official record
Conditions
Calcium Phosphate Kidney Stones
Interventions
OHCit- standard dose, Potassium Citrate, Placebo, OHCit- low dose
Dietary Supplement · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years to 99 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 15, 2026, 2:08 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight Adults

NCT03100058
View directory record Official record
Conditions
Obesity, Overweight
Interventions
LIK066, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
59
States / cities
Anniston, Alabama • Jasper, Alabama • Beverly Hills, California + 52 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Sep 15, 2026, 2:08 AM EDT
Completed Phase 2 Interventional

GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection

NCT01435226
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
GS-5885, GS-9451, tegobuvir, placebo to match tegobuvir, placebo to match RBV, Ribavirin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
37
States / cities
Tucson, Arizona • Anaheim, California • Beverly Hills, California + 30 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2013 · Synced Sep 15, 2026, 2:08 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)

NCT00761150
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
ABT-712, Placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
21 Years to 75 Years
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
32
States / cities
Tempe, Arizona • Tucson, Arizona • Anaheim, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Sep 15, 2026, 2:08 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy

NCT02112838
View directory record Official record
Conditions
IGA Nephropathy
Interventions
Fostamatinib 150 mg, Fostamatinib 100 mg, Placebo
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
4
States / cities
Palo Alto, California • Augusta, Georgia • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Sep 15, 2026, 2:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Buprenorphine Accumulation and Description of Its Metabolites During Co-Medication of Buprenorphine Transdermal System (BTDS) and Ketoconazole

NCT01259115
View directory record Official record
Conditions
Healthy
Interventions
Buprenorphine transdermal patch, Ketoconazole tablet, Placebo to match ketoconazole tablet
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years to 54 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 18, 2014 · Synced Sep 15, 2026, 2:08 AM EDT
Terminated Phase 2 Interventional

Effects of HQK-1001 in Patients With Sickle Cell Disease

NCT01601340
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Anemia, Sickle Cell Disorders, Hemoglobin S Disease, Sickling Disorder Due to Hemoglobin S
Interventions
HQK-1001, Placebo
Drug
Lead sponsor
HemaQuest Pharmaceuticals Inc.
Industry
Eligibility
12 Years to 60 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
11
States / cities
Mobile, Alabama • Oakland, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Sep 15, 2026, 2:08 AM EDT